Clinical Trial Detail

NCT ID NCT03059485
Title DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

Therapies

DC/AML Vaccine

DC/AML Vaccine + Durvalumab

Age Groups: senior adult

No variant requirements are available.